Evaluation of the effect of phosphodiesterase on equine platelet activation and the effect of antigen challenge on platelet phosphodiesterase activity in horses with recurrent airway obstruction

Bettina Dunkel Department of Veterinary Clinical Sciences, The Royal Veterinary College, North Mymms, Herts AL9 7TA, England.

Search for other papers by Bettina Dunkel in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Karen J. Rickards The Donkey Sanctuary, Sidmouth, Devon EX10 0NU, England.

Search for other papers by Karen J. Rickards in
Current site
Google Scholar
PubMed
Close
 BVSc, PhD
,
Dirk Werling Department of Pathology and Infectious Diseases, The Royal Veterinary College, North Mymms, Herts AL9 7TA, England.

Search for other papers by Dirk Werling in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Clive P. Page Sackler Institute of Pulmonary Pharmacology, Division of Pharmacology and Therapeutics, GKT School of Biomedical Sciences, King's College London, London Bridge, London SE1 9RT, England.

Search for other papers by Clive P. Page in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Fiona M. Cunningham Department of Veterinary Basic Sciences, The Royal Veterinary College, North Mymms, Herts AL9 7TA, England.

Search for other papers by Fiona M. Cunningham in
Current site
Google Scholar
PubMed
Close
 PhD

Abstract

Objective—To determine whether expression of equine platelet activation–dependent surface markers is influenced by phospodiesterase (PDE) isoenzyme activity and whether antigen challenge alters platelet PDE activity in horses with recurrent airway obstruction (RAO).

Animals—16 horses.

Procedures—7 healthy horses were used for in vitro experiments, 6 horses with RAO were used for antigen challenge, and 6 healthy horses were used as control animals. Three of the healthy horses had also been used in the in vitro experiments. Effects of PDE inhibition and activation of adenylyl cyclase on CD41/61 and CD62P expression on platelets and platelet-neutrophil aggregate formation in vitro were investigated via flow cytometry. Platelet PDE activity and sensitivity to inhibition of PDE3 and PDE5 isoenzymes were examined in horses with RAO and control horses before and after antigen challenge.

Results—Inhibition of PDE or activation of adenylyl cyclase significantly inhibited stimulus-induced expression of CD41/61 and CD62P (by approx 94% and 40%, respectively) and percentage of CD62P positive cells (by approx 30%). Only the PDE3 inhibitor, trequinsin, caused a significant (53%) reduction in platelet-neutrophil aggregate formation. Platelet PDE activity decreased following antigen challenge in RAO-affected horses and control horses. In horses with RAO, a significant increase in sensitivity of platelet PDE to inhibition by the PDE5 inhibitor zaprinast was observed after 5 hours.

Conclusions and Clinical Relevance—Results provided further evidence that PDE3 is an important regulator of equine platelet activation and suggested that changes in regulation of platelet PDE5 may contribute to antigen-induced response in horses with RAO.

Abstract

Objective—To determine whether expression of equine platelet activation–dependent surface markers is influenced by phospodiesterase (PDE) isoenzyme activity and whether antigen challenge alters platelet PDE activity in horses with recurrent airway obstruction (RAO).

Animals—16 horses.

Procedures—7 healthy horses were used for in vitro experiments, 6 horses with RAO were used for antigen challenge, and 6 healthy horses were used as control animals. Three of the healthy horses had also been used in the in vitro experiments. Effects of PDE inhibition and activation of adenylyl cyclase on CD41/61 and CD62P expression on platelets and platelet-neutrophil aggregate formation in vitro were investigated via flow cytometry. Platelet PDE activity and sensitivity to inhibition of PDE3 and PDE5 isoenzymes were examined in horses with RAO and control horses before and after antigen challenge.

Results—Inhibition of PDE or activation of adenylyl cyclase significantly inhibited stimulus-induced expression of CD41/61 and CD62P (by approx 94% and 40%, respectively) and percentage of CD62P positive cells (by approx 30%). Only the PDE3 inhibitor, trequinsin, caused a significant (53%) reduction in platelet-neutrophil aggregate formation. Platelet PDE activity decreased following antigen challenge in RAO-affected horses and control horses. In horses with RAO, a significant increase in sensitivity of platelet PDE to inhibition by the PDE5 inhibitor zaprinast was observed after 5 hours.

Conclusions and Clinical Relevance—Results provided further evidence that PDE3 is an important regulator of equine platelet activation and suggested that changes in regulation of platelet PDE5 may contribute to antigen-induced response in horses with RAO.

Contributor Notes

At the time of the study, Dr. Dunkel was a Horserace Betting Levy Board Training Scholar.

Address correspondence to Dr. Dunkel (bdunkel@rvc.ac.uk).
  • 1.

    Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001;62:11531161.

  • 2.

    Zhang W, Colman RW. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A. Blood 2007;110:14751482.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Dunkel B, Rickards KJ, Page CP, et alPhosphodiesterase isoenzymes in equine platelets and their influence on platelet adhesion. Am J Vet Res 2007;68:13541360.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Rickards KJ, Page CP, Hamblin AS, et alBiochemical and functional assessment of equine lymphocyte phosphodiesterases and protein kinase C. Vet Immunol Immunopathol 2004;98:153165.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Rickards KJ, Page CP, Lees P, et alDifferential inhibition of equine neutrophil function by phosphodiesterase inhibitors. J Vet Pharmacol Ther 2001;24:275281.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Lalko CC, Deppe E, Ulatowski D, et alEquine platelet CD62P (P-selectin) expression: a phenotypic and morphologic study. Vet Immunol Immunopathol 2003;91:119134.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Weiss DJ, Evanson OA, McClenahan D, et alShear-induced platelet activation and platelet-neutrophil aggregate formation by equine platelets. Am J Vet Res 1998;59:12431246.

    • Search Google Scholar
    • Export Citation
  • 8.

    Hamamoto M, Suga M, Takahashi Y, et alSuppressive effect of phosphodiesterase type 4 inhibition on systemic inflammatory responses after cardiopulmonary bypass. J Artif Organs 2006;9:144148.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Sanz MJ, Alvarez A, Piqueras L, et alRolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation. Br J Pharmacol 2002;135:18721881.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Schmitz G, Rothe G, Ruf A, et alEuropean Working Group on Clinical Cell Analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998;79:885896.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Robinson NE. International Workshop on Equine Chronic Airway Disease. Michigan State University 16–18 June 2000. Equine Vet J 2001;33:519.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Landells LJ, Spina D, Souness JE, et alA biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects. Pulm Pharmacol Ther 2000;13:231239.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Rickards KJ, Page CP, Cunningham FM. Allergen challenge alters lymphocyte phosphodiesterase activity in horses with heaves. Pulm Pharmacol Ther 2004;17:163172.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Chan SC, Hanifin JM. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med 1993;121:4451.

    • Search Google Scholar
    • Export Citation
  • 15.

    Sawai T, Ikai K, Uehara M. Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from patients with atopic dermatitis: correlation with respiratory atopy. Br J Dermatol 1998;138:846848.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Banner KH, Roberts NM, Page CP. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br J Pharmacol 1995;116:31693174.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Barber R, Baillie GS, Bergmann R, et alDifferential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 2004;287:L332L343.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Dunkel B, Rickards KJ, Page CP, et alPlatelet activation in ponies with airway inflammation. Equine Vet J 2007;39:557561.

  • 19.

    Foster AP, Cunningham FM. Differential superoxide anion generation by equine eosinophils and neutrophils. Vet Immunol Immunopathol 1997;59:225237.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Rickards KJ, Andrews MJ, Waterworth TH, et alDifferential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation. J Vet Pharmacol Ther 2003;26:277282.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Dunkel B, Rickards KJ, Werling D, et alNeutrophil and platelet activation in equine recurrent airway obstruction is associated with increased neutrophil CD13 expression, but not platelet CD41/61 and CD62P or neutrophil-platelet aggregate formation. Vet Immunol Immunopathol 2009;131:2532.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Segura D, Monreal L, Perez-Pujol S, et alAssessment of platelet function in horses: ultrastructure, flow cytometry, and perfusion techniques. J Vet Intern Med 2006;20:581588.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Peters MJ, Heyderman RS, Hatch DJ, et alInvestigation of platelet-neutrophil interactions in whole blood by flow cytometry. J Immunol Methods 1997;209:125135.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Fairbairn SM, Page CP, Lees P, et alEarly neutrophil but not eosinophil or platelet recruitment to the lungs of allergic horses following antigen exposure. Clin Exp Allergy 1993;23:821828.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Robinson NE, Olszewski MA, Boehler D, et alRelationship between clinical signs and lung function in horses with recurrent airway obstruction (heaves) during a bronchodilator trial. Equine Vet J 2000;32:393400.

    • Search Google Scholar
    • Export Citation
  • 26.

    Sweeney CR, Rossier Y, Ziemer EL, et alEffect of prior lavage on bronchoalveolar lavage fluid cell population of lavaged and unlavaged lung segments in horses. Am J Vet Res 1994;55:15011504.

    • Search Google Scholar
    • Export Citation
  • 27.

    Lowry OH, Rosebrough NJ, Farr AL, et alProtein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265275.

  • 28.

    Dunkern TR, Hatzelmann A. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal 2005;17:331339.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Rickards KJ, Page CP, Lees P, et alPhosphodiesterase activity in neutrophils from horses with chronic obstructive pulmonary disease. Vet Immunol Immunopathol 2000;76:319330.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Young ME, Leighton B. Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle. Biochem J 1998;329:7379.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Sekiguchi M, Aoki Y, Konno S, et alThe effects of cilostazol on nerve conduction velocity and blood flow: acute and chronic cauda equina compression in a canine model. Spine 2008;33:26052611.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Onoda K, Ohashi K, Hashimoto A, et alInhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery. Ann Thorac Cardiovasc Surg 2008;14:230237.

    • Search Google Scholar
    • Export Citation
  • 33.

    Kumar M, Bhattacharya V. Cilostazol: a new drug in the treatment intermittent claudication. Recent Pat Cardiovasc Drug Discov 2007;2:181185.

  • 34.

    Cesarini C, Hamilton E, Picandet V, et alTheophylline does not potentiate the effects of a low dose of dexamethasone in horses with recurrent airway obstruction. Equine Vet J 2006;38:570573.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Lavoie JP, Pasloske K, Joubert P, et alLack of clinical efficacy of a phosphodiesterase-4 inhibitor for treatment of heaves in horses. J Vet Intern Med 2006;20:175181.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 2006;117:12371243.

  • 37.

    Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol 2006;147(suppl 1):S252S257.

  • 38.

    Fan Chung K. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006;533:110117.

Advertisement